Monocyte and microglial activation in patients with mood-stabilized bipolar disorder

Journal of Psychiatry and Neuroscience

Volumn 40, Issue 4, 2015, Pages 250-258

  Jakobsson, Joel ^a   Bjerke, Maria ^a   Sahebi, Sara ^a   Isgren, Anniella ^a   Ekman, Carl Johan ^b   Sellgren, Carl ^b   Olsson, Bob ^a   Zetterberg, Henrik ^a,c   Blennow, Kaj ^a   Pålsson, Erik ^a   Landén, Mikael ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM ALBUMIN; TISSUE INHIBITOR OF METALLOPROTEINASE; ADIPOCYTOKINE; BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN; CD14 ANTIGEN; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1; LECTIN; PSYCHOTROPIC AGENT; TIMP1 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; BIPOLAR DISORDER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; PATHOPHYSIOLOGY; BLOOD; CEREBROSPINAL FLUID; IMMUNOLOGY; MIDDLE AGED;

ADIPOKINES; ADULT; ANTIGENS, CD14; BIOMARKERS; BIPOLAR DISORDER; CHEMOKINE CCL2; CHITINASE-3-LIKE PROTEIN 1; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LECTINS; MALE; MICROGLIA; MIDDLE AGED; MONOCYTES; PSYCHOTROPIC DRUGS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84934768448     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.140183     Document Type: Article

References (50)

1. Belmaker RH. Bipolar disorder. N Engl J Med 2004;351:476-86.
2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011;68:241-51.
3. Leboyer M, Soreca I, Scott J, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord 2012;141:1-10.
4. Magalhães PV, Kapczinski F, Nierenberg AA, et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatr Scand 2012;125:303-8.
5. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35:804-17.
6. Goldstein BI, Kemp DE, Soczynska JK, et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009; 70:1078-90.
7. Modabbernia A, Taslimi S, Brietzke E, et al. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74:15-25.
8. Munkholm K, Brauner JV, Kessing LV, et al. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013;47:1119-33.
9. Rao JS, Harry GJ, Rapoport SI, et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010;15:384-92.
10. Haarman BC, Riemersma-Van der Lek RF, de Groot JC, et al. Neuroinflammation in bipolar disorder - a [C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun 2014;40:219-25.
11. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995;20:111-6.
12. Beumer W, Gibney SM, Drexhage RC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol 2012;92:959-75.
13. Bromander S, Anckarsater R, Kristiansson M, et al. Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study. J Neuroinflammation 2012;9:242.
14. Maier B, Laurer HL, Rose S, et al. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma 2005;22:822-35.
15. Söderlund J, Olsson SK, Samuelsson M, et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J Psychiatry Neurosci 2011;36:114-8.
16. Dugué B, Leppanen E, Grasbeck R. Preanalytical factors and the measurement of cytokines in human subjects. Int J Clin Lab Res 1996;26:99-105.
17. Malekzadeh A, de Groot V, Beckerman H, et al. Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. Methods 2012;56:508-13.
18. Zetterberg H, Jakobsson J, Redsäter M, et al. Blood-cerebrospinal barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Res 2014;217:143-6.
19. Lautner, R., Mattsson, N., Scholl, M., et al. Biomarkers for microglial activation in Alzheimer's disease. Int J Alzheimers Dis 2011; 2011: 939426.
20. Lively S, Schlichter LC. The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J Neuroinflammation 2013;10:75.
21. Brew, K. & Nagase, H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010;1803:55-71.
22. Tsai, H.C., Shi, M.H., Lee, S.S., et al. Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with meningitis. Clin Microbiol Infect 2011; 17:780-4.
23. Shukla V, Shakya AK, Dhole TN, et al. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of children with Japanese encephalitis virus infection. Arch Virol 2013; 158:2561-75.
24. Lorenzl S, Albers DS, LeWitt PA, et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003;207:71-6.
25. Bjerke M, Zetterberg H, Edman A, et al. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease. J Alzheimers Dis 2011;27: 665-76.
26. Rydén E, Johansson C, Blennow K, et al. Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J Neural Transm 2009;116:1667-74.
27. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003;53:1028-42.
28. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33, quiz 34-57.
29. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993;88:791-804.
30. Tibbling G, Link H, Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest 1977;37:385-90.
31. Hinojosa AE, Garcia-Bueno B, Leza JC, et al. CCL2/MCP-1 modulation of microglial activation and proliferation. J Neuroinflammation 2011;8:77.
32. Mélik-Parsadaniantz S, Rostene W. Chemokines and neuromodulation. J Neuroimmunol 2008;198:62-8.
33. Moreira MA, Tilbery CP, Monteiro LP, et al. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 2006;114:109-13.
34. Bonneh-Barkay D, Bissel SJ, Wang G, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 2008; 173:130-43.
35. Rathcke, C.N. & Vestergaard, H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 2006;55:221-227.
36. Li, H., Li, Q., Du, X., et al. Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. J Cereb Blood Flow Metab 2011; 31: 2106-2115.
37. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996;93:8455-9.
38. Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord 2007;9:743-53.
39. Ichiyama T, Okada K, Lipton JM, et al. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res 2000;857:246-51.
40. Yao Y, Tsirka SE. Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell Mol Life Sci 2014;71:683-97.
41. Bas S, Gauthier BR, Spenato U, et al. CD14 is an acute-phase protein. J Immunol 2004;172:4470-9.
42. Marcos V, Latzin P, Hector A, et al. Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases. Respir Res 2010;11:32.
43. Haider DG, Leuchten N, Schaller G, et al. C-reactive protein is expressed and secreted by peripheral blood mononuclear cells. Clin Exp Immunol 2006;146:533-9.
44. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-3.
45. Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett 2008;29:117-24.
46. Severance EG, Gressitt KL, Stallings CR, et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 2013;148:130-7.
47. Brietzke E, Kauer-Sant'Anna M, Teixeira AL, et al. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav Immun 2009;23:1079-82.
48. Drexhage RC, Padmos RC, de Wit H, et al. Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: Association with the metabolic syndrome in patients? Schizophr Res 2008;102:352-5.
49. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 2010;5:e9166.
50. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-41.